AcquiredStartups
Biggest in J.P. Morgan Life Sciences Private Capital
Investor

J.P. Morgan Life Sciences Private Capital

1Exits tracked$1.5bnDisclosed value$1.5bnMedian price0Acquihires

Startups backed by J.P. Morgan Life Sciences Private Capital that were acquired: 1 exit so far, with the buyer, the price where disclosed and every source.

Photo: Maggie Bartlett, NHGRI / Wikimedia Commons, Public domain
Healthtech & bio · Wellesley Hills

Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion

J.P. Morgan's life sciences venture arm set up the Massachusetts biotech only last year, and its lead antibody for two blood cancers has not yet been tested in people.

Price$1.5bnRaisedn/aLast stageSeries BBuyer typeCorporate
Latest in J.P. Morgan Life Sciences Private CapitalMore stories here soon.